Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?

Journal of Clinical Oncology

Volumn 23, Issue 29, 2005, Pages 7350-7360

  Brenton, James D ^a   Carey, Lisa A ^a   Ahmed, Ashour ^a   Caldas, Carlos ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; RNA; TAMOXIFEN; TUMOR MARKER;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CLINICAL FEATURE; ENDOCRINE TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; FORECASTING; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC DIFFERENCE; GENOMICS; HUMAN; INDIVIDUALIZATION; METHODOLOGY; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REVIEW; TREATMENT RESPONSE; TUMOR GENE; BREAST TUMOR; CLASSIFICATION; FEMALE; GENETIC MARKER; GENETICS; PREDICTION AND FORECASTING;

BREAST NEOPLASMS; FEMALE; FORECASTING; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 28344454000     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.3845     Document Type: Review

References (66)

1. Peto R, Boreham J, Clarke M, et al: UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 355:1822, 2000
2. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. Caldas C, Aparicio SA: The molecular outlook. Nature 415:484-485, 2002
4. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
5. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
6. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100:10393-10398, 2003
7. Weigelt B, Glas AM, Wessels LF, et al: Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A 100:15901-15905, 2003
8. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
9. Callagy G, Cattaneo E, Daigo Y, et al: Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12:27-34, 2003
10. Abd El-Rehim DM, Pinder SE, Paish CE, et al: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203:661-671, 2004
11. Jacquemier J, Ginestier C, Rougemont J, et al: Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 65:767-779, 2005
12. Carey LA, Perou CM, Dressier LG, et al: Race and the poor prognosis basal-like breast cancer (BBC) phenotype in the population-based Carolina Breast Cancer Study. J Clin Oncol, 2004 (suppl; abstr 9510)
13. Rouzier R, Anderson K, Hess KR, et al: Basal and luminal types of breast cancer defined by gene expression patterns respond differently to neoadjuvant chemotherapy. San Antonio Breast Cancer Symposium. San Antonio, TX, 2004 (abstr 1026)
14. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of the basal-like breast cancer (BBC) phenotype. San Antonio Breast Cancer Symposium. San Antonio, TX, 2004 (abstr 1023)
15. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
16. Paik S, Shak S, Tang G, et al: Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. J Clin Oncol 23:6s, 2005 (suppl; abstr 510)
17. Paik S, Shak S, Tang G, et al: Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20, San Antonio Breast Cancer Symposium. San Antonio, TX, 2004 (abstr 24)
18. Gianni L, Zambetti M, Clark K, et al: Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. J Clin Oncol, 2004 (suppl: abstr 501)
19. Miller KD, Burstein HJ, Elias A, et al: Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol, 2005 (suppl; abstr 563)
20. Colditz GA, Rosner BA, Chen WY, et al: Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96:218-228, 2004
21. Berry D, Cirrincione C, Henderson IC, et al: Effects of improvements in chemotherapy on disease-free and overall survival of estrogen receptor negative, node positive breast cancer: 20 years experience of the CALGB and US Breast Intergroup, San Antonio Breast Cancer Symposium. San Antonio, TX, 2004 (abstr 29)
22. Romond E, Perez EA, Bryant J, et al: Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Presented at 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005
23. Perez EA, Suman V, Davidson N, et al: NCCTG N9831 May 2005 Update. J Clin Oncol, 2005 Presented at 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005
24. Piccart-Gebhart M: First Results of the HERA trial: A randomized three-arm multi-center comparison of 1 year herceptin, 2 years herceptin, or no herceptin in women with HER-2 positive primary breast cancer who have completed adjuvant chemotherapy. J Clin Oncol, 2005 Presented at 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005
25. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004
26. Tripathy D, Hassan S, Verma U, et al: Phenotypic and proteomic alterations of acquired trastuzumab resistence. J Clin Oncol, 2005 (suppl; abstr 3121)
27. Abd El-Rehim DM, Ball G, Pinder SE, et al: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340-350, 2005
28. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004
29. Chlebowski RT, Chen Z, Anderson GL, et al: Ethnicity and breast cancer: Factors influencing differences in incidence and outcome. J Natl Cancer Inst 97:439-448, 2005
30. Kennedy RD, Quinn JE, Mullan PB, et al: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659-1668, 2004
31. Sartor C, Zhou H, Perou CM, et al: Basal-like breast tumor-derived cell lines are growth inhibited and radiosensitized by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. San Antonio Breast Cancer Symposium. San Antonio, TX, December 8-11, 2004
32. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemtcal and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374, 2004
33. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102:3738-3743, 2005
34. Levine MN, Browman GP, Gent M, et al: When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol 9:348-356, 1991
35. Simon R: Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br J Cancer 89: 1599-1604, 2003
36. Altman DG: Systematic reviews of evaluations of prognostic variables. BMJ 323:224-228, 2001
37. Simon R, Radmacher MD, Dobbin K, et al: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95:14-18, 2003
38. Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100:9440-9445, 2003
39. Simon R: When is a genomic classifier ready for prime time? Nat Clin Pract Oncol 1:4-5, 2004
40. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
41. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
42. Ahr A, Karn T, Solbach C, et al: Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359:131-132, 2002
43. Huang E, Cheng SH, Dressman H, et al: Gene expression predictors of breast cancer outcomes. Lancet 361:1590-1596, 2003
44. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003
45. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005
46. Lee JK, Bussey KJ, Gwadry FG, et al: Comparing cDNA and oligonucleotide array data: Concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol 4:R82, 2003
47. Zorn KK, Jazaeri AA, Awtrey CS, et al: Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 9:4811-4818, 2003
48. Ahmed AA, Vias M, Iyer NG, et al: Microarray segmentation methods significantly influence data precision. Nucleic Acids Res 32:e50, 2004
49. Ein-Dor L, Kela I, Getz G, et al: Outcome signature genes in breast cancer: Is there a unique set? Bioinformatics 21:171-178, 2005
50. Michiels S, Koscielny S, Hill C: Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet 365:488-492, 2005
51. Bair E, Tibshirani R: Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2:E108, 2004
52. Kang Y, Siegel PM, Shu W, et al: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549, 2003
53. Woelfle U, Cloos J, Sauter G, et al: Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63:5679-5684, 2003
54. Minn AJ, Kang Y, Serganova I, et al: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115:44-55, 2005
55. Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616, 2004
56. Reid JF, Lusa L, De Cecco L, et al: Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst 97:927-930, 2005
57. Simon R: Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 97:866-867, 2005
58. Eden P, Ritz C, Rose C, et al: Good old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40:1837-1841, 2004
59. Kattan MW: Evaluating a new marker's predictive contribution. Clin Cancer Res 10:822-824, 2004
60. Ayers M, Symmans WF, Stec J, et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-2293, 2004
61. Iwao-Koizumi K, Matoba R, Ueno N, et al: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23:422-431, 2005
62. Chang JC, Wooten EC, Tsimelzon A, et al: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23:1169-1177, 2005
63. Burstein HJ, Winer EP: HER2 or not HER2: That is the question. J Clin Oncol 23:3656-3659, 2005
64. Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23: 2020-2027, 2005
65. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005
66. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991